Wang Ming, Liu Chunmei, Wang Yingjie, Jamil Muhammad, Alhomrani Majid, Alamri Abdulhakeem S, Alsanie Walaa F, Alsharif Abdulaziz, Ali Mubarik, Jabeen Norina
Department of Oncology, Hebei Yanda Hospital Langfang 065200, Hebei, China.
PARC Arid Zone Research Centre Dera Ismail Khan 29050, Pakistan.
Am J Transl Res. 2024 Feb 15;16(2):400-414. doi: 10.62347/PWZA6242. eCollection 2024.
Bone morphogenetic protein 1 (BMP1) is a metalloprotease that plays a role in activating both transforming growth factor-β (TGF-β) and BMP signaling pathways. TGF-β has been identified as a factor initiating and facilitating cancer development. Consequently, we propose the hypothesis that dysregulation of BMP1 could potentially contribute to the onset and advancement of human cancers.
In this research, we aimed to analyze BMP1 expression level and the associated clinical outcomes across various cancers using online cancer OMICS databases, advanced Bioinformatics tools, and molecular analyses.
The outcomes of our web server-based expression analysis indicated an up-regulation of BMP1 in a majority of the human cancers examined. External validation using clinical samples also showed higher expression of BMP1. Moreover, heightened BMP1 expression exhibited a noteworthy correlation with reduced overall survival (OS) duration in Bladder Cancer (BLCA), Kidney Renal Clear Cell Carcinoma (KIRC), and Lung Adenocarcinoma (LUAD) patients. This suggests a substantial involvement of the BMP1 gene in the development and progression of these three types of cancers. The major signaling pathways related with BMP1 enriched genes were "ECM-receptor interaction, Amoebiasis, Focal adhesion, Protein digestion and absorption, progesterone-mediated, PI3K-Akt signaling pathway, and platelet activation". Moreover, we also explored some interesting correlations among BMP1 expression and its DNA promoter methylation level, CD8+ T immune cells level, and genetic variations.
In conclusion, our study has provided some solid basis for BMP1 to be used as a reliable common biomarker for BLCA, KIRC, and LUAD patients.
骨形态发生蛋白1（BMP1）是一种金属蛋白酶，在激活转化生长因子-β（TGF-β）和BMP信号通路中发挥作用。TGF-β已被确定为启动和促进癌症发展的一个因素。因此，我们提出假说，即BMP1的失调可能潜在地促进人类癌症的发生和进展。
在本研究中，我们旨在使用在线癌症组学数据库、先进的生物信息学工具和分子分析，分析BMP1在各种癌症中的表达水平及相关临床结果。
基于网络服务器的表达分析结果表明，在大多数所检测的人类癌症中BMP1表达上调。使用临床样本进行的外部验证也显示BMP1表达更高。此外，BMP1表达升高与膀胱癌（BLCA）、肾透明细胞癌（KIRC）和肺腺癌（LUAD）患者的总生存期（OS）缩短显著相关。这表明BMP1基因在这三种癌症的发生和发展中大量参与。与BMP1富集基因相关的主要信号通路为“细胞外基质受体相互作用、阿米巴病、粘着斑、蛋白质消化和吸收、孕酮介导、PI3K-Akt信号通路和血小板活化”。此外，我们还探讨了BMP1表达与其DNA启动子甲基化水平、CD8 + T免疫细胞水平和基因变异之间的一些有趣相关性。
总之，我们的研究为BMP1用作BLCA、KIRC和LUAD患者可靠的通用生物标志物提供了一些坚实的依据。
